Regenerative medicine company Orthocell (ASX:OCC) has announced the results from its 2018 Annual Quality Study.
The study shows an 82 per cent success rate using Ortho-ATI stem cell therapy for the treatment of chronic tendon injuries.
According to managing director Paul Anderson, “We are delighted by these results which provide strong evidence that Ortho-ATI is a breakthrough technology and significantly improves patients’ lives. This novel therapy alleviates chronic pain, restores tendon structure and enables people to return to normal function at home and work.
"Ortho-ATI has the potential to deliver significant socio-economic benefits, including improved individual productivity and reduced health care costs.”
The company said it conducts the annual study to capture patient feedback following treatment of chronic tendon injuries with Orthocell’s Ortho-ATI stem cell therapy.
The 2018 study indicated 82 per cent of patients are ‘satisfied’ to ‘extremely satisfied’ with how Ortho-ATI relieved symptoms such as chronic pain and improved their ability to perform everyday activities at home and at work.